Allergology: Introduction and Physiopathological Bases of Allergic Diseases

Allergology and Immunology · Clinical Specialties

How it begins

Un compendio científico y de referencia médica detallada, orientado a especialistas en alergología, inmunología y disciplinas médicas afines. Aborda de manera rigurosa la ontogenia celular, las cascadas de señalización molecular, la genética de la atopia, los mecanismos de hipersensibilidad, la teoría de la barrera epitelial y la terapéutica biológica avanzada.

What it covers

1. Ontogeny of the Allergic Immune System and Epithelial Barriers
2. Presentation of Antigens, Dendritic Cells and Immune Synapses
3. T Helper Lymphocytes and Their Phenotypic Plasticity
4. B Lymphocytes, Isotype Change and Regulation of IgE Synthesis
5. The High Affinity Receiver (FcεRI) and Low Affinity Receiver (FcεRII/CD23)
6. · High Affinity Receptor for IgE (FcεRI)
7. · Low Affinity Receptor for IgE (FcεRII / CD23)
8. Mast Cells and Basophils: Ontogeny, Receptors and Non-IgE Activation
9. · Non-IgE Activation Mediated by the MRGPRX2 Receptor
10. Eosinophils: Cell Biology and Cationic Granulation Proteins
11. · Cationic Proteins of Secondary Granules
12. Histamine and its Receptors (H1, H2, H3, H4)
13. Lipid Mediators of De Novo Synthesis
14. · The 5-Lipoxygenase Pathway: Cystenyl Leukotrienes (CysLTs)
15. · The Cycloxygenase Pathway: Prostaglandin D2 (PGD2)
16. Chemokines, Key Cytokines and Epithelial Alarmins
17. · The Type 2 Cytokine Trio
18. · Epithelial Alarmins and Type 2 Innate Lymphoid Cells (ILC2)
19. Gell and Coombs Classification Revisited
20. Type I Hypersensitivity (Immediate)
21. · 1. Sensitization Phase (Asymptomatic)
22. · 2. Early Effector Phase (Minutes)
23. · 3. Late Effector Phase (4 to 24 Hours)
24. Type II and Type III Hypersensitivity in the Context of Allergology
25. · Type II Mechanism (Blood Cell Haptenization)
26. · Type III Mechanism (Serum Sickness and Vasculitis)
27. Type IV Hypersensitivity: Subtypes and Complex Skin Reactions
28. · Pathophysiology of Severe Cutaneous Adverse Drug Reactions (SCARs)
29. Physicochemistry of Allergens and Cross Reactivity
30. Respiratory Allergens (Pneumoallergens)
31. · 1. House Dust Mites (*Dermatophagoides pteronyssinus* and *D. farinae*)
32. · 2. Pollens (Grasses, Trees and Weeds)
33. · 3. Domestic Animal Epithelia
34. Food Allergens (Trophoallergens)
35. · Oral Allergy Syndrome (OSS)
36. Occupational Allergens, Hymenoptera Venoms and Chemical Haptens
37. · Hymenoptera Poisons (Bees and Wasps)
38. · Chemical Haptens and Contact Immunity
39. Atopy Genomics: Susceptibility Loci
40. Epigenetics in Allergy: DNA Methylation and Histones
41. The Hygiene Hypothesis Revisited and the Microbiome Theory
42. Bronchial Asthma: Phenotypes, Endotypes and Airway Remodeling
43. · T2-High Endotype (Eosinophilic / Type 2)
44. · T2-Low Endotype (Neutrophilic or Paucigranulocytic)
45. Allergic Rhinitis and Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
46. Atopic Dermatitis: Filaggrin Dysfunction, Barrier and Neurogenic Inflammation
47. · Genetic Barrier Dysfunction: The Filaggrin Gene (*FLG*)
48. · Colonization and Pathogenic Role of *Staphylococcus aureus*
49. · The Pruritus and Neurogenic Inflammation Pathway
50. Food Allergies and Immuno-Gastroenterology: From Anaphylaxis to Eosinophilic Esophagitis
51. · Systemic Mediated IgE Reactions
52. · Non-IgE Mediated Reactions: Food Protein Induced Enterocolitis Syndrome (FPIES)
53. · Eosinophilic Esophagitis (EoE)
54. Systemic Anaphylaxis: Pathophysiology of Anaphylactic Shock
55. · Hepatophysiology of Hemodynamic Changes in Shock
56. Molecular Component Diagnosis (CRD) and In Vitro Functional Tests
57. · Clinical Advantages of Molecular Diagnosis
58. · The Basophil Activation Test (BAT)
59. Allergen Immunotherapy (ITA): Immunological Tolerance Mechanisms
60. Immunobiologicals and Precision Therapies in Complex Allergic Pathologies
61. · Omalizumab (Anti-IgE)
62. · Dupilumab (Anti-IL4Rα)
63. · Antibodies Directed against the Eosinophil Axis
64. · Tezepelumab (Anti-TSLP)
65. Intervention Algorithm in Severe Asthma and Type 2 Pathologies